| Identification | More | [Name]
N-Acetyl-L-leucine | [CAS]
1188-21-2 | [Synonyms]
2-(ACETYLAMINO)-4-METHYLPENTANOIC ACID
AC-DL-LEU-OH
ACETYL-DL-LEUCINE
ACETYL-DL-LEUCINE, N-
ACETYL-L-LEUCINE
AC-LEUCINE
AC-LEU-OH
AKOS BBS-00004735
IFLAB-BB F0777-0821
N-ACETYL-DL-LEU
N-ACETYL-DL-LEUCINE
N-ACETYL LEUCINE
N-ACETYL-L-LEUCINE
N-ALPHA-ACETYL-DL-LEUCINE
N-ALPHA-ACETYL-L-LEUCINE
(S)-2-ACETYLAMINO-4-METHYL-PENTANOIC ACID
(S)-N-Acetylleucine
Leucine, N-acetyl-, L-
L-Leucine, N-acetyl-
N-Acetyl-L-lenucine | [EINECS(EC#)]
214-706-3 | [Molecular Formula]
C8H15NO3 | [MDL Number]
MFCD00026498 | [Molecular Weight]
173.21 | [MOL File]
1188-21-2.mol |
| Chemical Properties | Back Directory | [Appearance]
White crystalline powder | [Melting point ]
187-190 °C(lit.)
| [alpha ]
-24.5 º (c=4, MeOH) | [Boiling point ]
303.86°C (rough estimate) | [density ]
1.1599 (rough estimate) | [refractive index ]
-22 ° (C=5, EtOH) | [storage temp. ]
−20°C
| [solubility ]
DMSO (Slightly), Ethanol (Slightly), Water (Slightly, Heated) | [form ]
Crystalline Powder | [pka]
3.67±0.10(Predicted) | [color ]
White | [Optical Rotation]
[α]25/D 23±3°, c = 2 in ethanol | [Water Solubility ]
0.81 g/100 mL (20 ºC) | [BRN ]
1724849 | [Major Application]
peptide synthesis | [InChI]
1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1 | [InChIKey]
WXNXCEHXYPACJF-ZETCQYMHSA-N | [SMILES]
CC(C)C[C@H](NC(C)=O)C(O)=O | [CAS DataBase Reference]
1188-21-2(CAS DataBase Reference) | [NIST Chemistry Reference]
L-leucine, n-acetyl-(1188-21-2) | [EPA Substance Registry System]
1188-21-2(EPA Substance) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S24/25:Avoid contact with skin and eyes .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [WGK Germany ]
3
| [TSCA ]
Yes | [HazardClass ]
IRRITANT | [HS Code ]
29241990 | [Storage Class]
11 - Combustible Solids |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder | [Uses]
N-Acetyl-L-(-)-leucine is used in the preparation of small molecule inhibitors of anti-apoptotic Bcl-2 family proteins. Also used in the preparation of amphiphilic copolymers involving hydrophobic amino acid and oligopeptide side chains for optical tumor imaging in vivo. | [Definition]
ChEBI: The N-acetyl derivative of L-leucine. | [reaction suitability]
reaction type: C-H Activation
reaction type: solution phase peptide synthesis
reagent type: catalyst
reaction type: Peptide Synthesis | [in vivo]
Levacetylleucine (60 mg/kg, i.v., administration on days 1, 2 and 3 for 15 days) decreases the postural imbalance scores and accelerates the course of postural compensation induced by UL in rats[3].
Levacetylleucine (100 mg/kg, oral gavage, administration daily for 28 days) attenuates cortical cell death afer traumatic brain injury (TBI) in N-Acetyl-L-leucine-treated TBI mouse cortices[4].
| Animal Model: | Male Sprague-Dawley rats (mean 400±20 g, age 3 months) after chemical UL[3] | | Dosage: | 60 mg/kg | | Administration: | i.v., 15 days | | Result: | Significantly decreased the postural imbalance scores on 7 day and accelerated the course of postural compensation by about 6 days in rats. |
| Animal Model: | C57/BL6 mice[4] | | Dosage: | 100 mg/kg | | Administration: | oral gavage, administration daily for 1-28 days | | Result: | Did not afect food intake and body weight in mice. |
| Animal Model: | N-Acetyl-L-leucine-treated TBI mouse cortices[4] | | Dosage: | 100 mg/kg | | Administration: | oral gavage, administration daily for 28 days | | Result: | Prevented cortical cell death which peaks at early time points (day 1) afer TBI in N-Acetyl-L-leucine-treated TBI mouse cortices. |
| [IC 50]
Human Endogenous Metabolite |
|
|